Safety application of novel coronavirus pneumonia antiviral drugs.
Adverse Drug Reactions Journal
; 22(2):95-102, 2020.
Artículo
en Chino
| EMBASE | ID: covidwho-2292806
ABSTRACT
Three antiviral drugs, including interferon alpha (aerosol inhalation), lopinavir/ritonavir (oral medication), and ribavirin (intravenous infusion), are recommended by Diagnosis and Treatment of Novel Coronavirus Pneumonia (revised version, the 5th ed), which was issued by the National Health Commission of People's Republic of China and National Administration of traditional Chinese Medicine. In addition, clinical trials on a new antiviral drug-remdesivir which is not yet on the market has also been launched in China. Medication safety related data on treatment for infections of severe acute respiratory syndrome coronavirus, middle respiratory syndrome coronavirus, human immunodeficiency virus, lopinavir/ritonavir, and ribavirin, safety data of remdesivir in animal experiment, phase I clinical trials and clinical trials of treating Ebola virus infection, and preliminary reports of treatment in novel coronavirus pneumonia were briefly reviewed, aiming to provide evidence for clinical safety medication.Copyright © 2020 by the Chinese Medical Association.
Antiviral agents; Coronavirus infections; Middle East respiratory syndrome coronavirus; SARS virus; coronavirus disease 2019; Coronavirus infection/dt [Drug Therapy]; drug safety; Ebola hemorrhagic fever; human; Human immunodeficiency virus infection; phase 1 clinical trial (topic); preliminary data; priority journal; review; alpha interferon/dt [Drug Therapy]; alpha interferon/ih [Inhalational Drug Administration]; anticoronavirus agent/dt [Drug Therapy]; lopinavir plus ritonavir/dt [Drug Therapy]; lopinavir plus ritonavir/po [Oral Drug Administration]; remdesivir/dt [Drug Therapy]; ribavirin/dt [Drug Therapy]; ribavirin/iv [Intravenous Drug Administration]
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Idioma:
Chino
Revista:
Adverse Drug Reactions Journal
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS